BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2481528)

  • 1. [Serum immunoglobulin concentrations in patients following bone marrow transplantation and preventive administration of high-dose nonspecific or normal-dose CMV-specific immunoglobulin].
    Berger C; Gratwohl A; Doran JE; Scherz R; Baumgartner C; Morell A; Bachmann B; Spaeth PJ; Tichelli A; Speck B
    Beitr Infusionsther; 1989; 24():112-21. PubMed ID: 2481528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of immunoglobulins and of antibody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmune globulin.
    Gratwohl A; Doran JE; Bachmann P; Scherz R; Späth P; Baumgartner C; Perret B; Berger C; Nissen C; Tichelli A
    Bone Marrow Transplant; 1991 Oct; 8(4):275-82. PubMed ID: 1661632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
    Chaushu G; Chaushu S; Slavin S; Or R; Garfunkel AA; Yefenof E
    Bone Marrow Transplant; 1996 Feb; 17(2):237-41. PubMed ID: 8640173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of cytomegalovirus IgG antibody following infusion of a hyperimmune globulin preparation in allogeneic marrow transplant recipients.
    Reusser P; Osterwalder B; Gratama JW; The TH; Gratwohl A; Speck B
    Bone Marrow Transplant; 1989 May; 4(3):267-72. PubMed ID: 2543469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incidence and prognostic value of cytomegalovirus-specific antibodies of the IgM class in kidney transplant recipients].
    Eichler C; Kaden J; May G
    Z Urol Nephrol; 1990 Aug; 83(8):425-9. PubMed ID: 2173294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients.
    Rand KH; Houck H; Ganju A; Babington RG; Elfenbein GJ
    Bone Marrow Transplant; 1989 Nov; 4(6):679-83. PubMed ID: 2555005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].
    Bordigoni P; Janot C; Aymard JP; Witz F; Bené MC; Legras B; Schoonemann F; Olive D; Streiff F
    Nouv Rev Fr Hematol (1978); 1987; 29(5):289-93. PubMed ID: 2830588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients.
    Bosi A; De Majo E; Guidi S; Parri F; Saccardi R; Vannucchi AM; Fanci R; Ferrini PR
    Haematologica; 1990; 75(2):109-12. PubMed ID: 2162799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
    Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
    Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.
    Condie RM; O'Reilly RJ
    Dev Biol Stand; 1982; 52():501-13. PubMed ID: 6299859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific anti-cytomegalovirus immunoglobulins in the prevention of cytomegalovirus infections in bone marrow allografts].
    Huart JJ; Baume D; Jouet JP
    Ann Med Interne (Paris); 1987; 138(5):372-4. PubMed ID: 2823667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cytomegalovirus infection in an outpatient setting--laboratory markers and clinical aspects.
    Just-Nübling G; Korn S; Ludwig B; Stephan C; Doerr HW; Preiser W
    Infection; 2003 Oct; 31(5):318-23. PubMed ID: 14556056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of cytomegalovirus avidity testing by adjusting the concentration of CMV-specific IgG in test samples.
    Dangel V; Bäder U; Enders G
    J Clin Virol; 2006 Mar; 35(3):303-9. PubMed ID: 16298547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status.
    Lutz E; Ward KN; Szydlo R; Goldman JM
    J Med Virol; 1996 May; 49(1):61-5. PubMed ID: 8732861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
    Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.